Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a spinout from KitoZyme, develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as invalidating OsteoArthritis, skin aging and ophthalmology.
Our productKiOmed Pharma's innovative pipeline is based on a solid building block exclusive technology: Carboxymethyl Chitosan (CM-chitosan), a medical-grade natural chitosan derivative with a high purity.
The patented technology KiOmedine® offers competitive advantages thanks to its immunocompatibility and unique structure. Our scientific team has conducted a large number of safety and efficacy studies to demonstrate the unrivaled properties of the KiOmedine® technology in various applications :
Our technology brings high clinical value to therapeutic solutions and is a technology of choice, suitable for injectable formulations and implantable devices.
OsteoArthritis is a degenerative joint disease that affects more than 100 million patients worldwide. It is a debilitating and painful condition that can cause extreme discomfort and limit mobility in those affected. In order to find the most effective treatments, research and development must be undertaken to find new ways of helping those affected by OsteoArthritis find relief and live better lives. Thanks to a unique structure that differs from hyaluronic acid and natural chitosan, our technology KiOmedine® is a component of choice to tackle Osteoarthritis discomfort and other symptoms.
Thanks to free radical scavenging, KiOmedine®-based dermal fillers provide tunable tissues filling properties with unique skin protection and hydration while stimulating collagen synthesis.
Thanks to its unique hydrating and lubricating properties, as well as its ability to protect tissues against oxidative stress, KiOmedine® is a component of choice in eyedrops formulations or for more innovative treatments of the posterior segment.
KiOmed Pharma, based in Belgium, is a biotech company that focuses on the development, manufacture and distribution of safe and effective medical devices based on KiOmedine® CM-Chitosan, our innovative and exclusive animal-free bioresorbable biopolymer.
Through a series of comparative, pre-clinical and clinical studies, KiOmed Pharma repeatedly demonstrated that its exclusive technology KiOmedine® offers unique and sustainable attributes in comparison with competitive products. Our multidisciplinary team experts continually strive to advance innovative solutions to address unmet needs in the treatment of invalidating OsteoArthritis symptoms, dry eye disease and skin aging pathologies.
Discover our team
If you are interested in becoming a distributor for our KioMedinevsone product, contact us at moc.amrahpdemoik@db
+32 (0)4 228 80 40
moc.amrahpdemoik@tcatnoc
If you would like to report a complaint or concern related to the quality of one of our marketed products, please contact us here: moc.amrahpdemoik@ygolotamuehr-ecnaligiv
Production : Rue Haute Claire 4 - 4040 Herstal - Belgium
Operations & R&D : Legia Park I Boulevard Patience et Beaujonc 3, 4000 Liège - Belgium
